Theravance Biopharma, Inc.·4

Feb 24, 7:24 PM ET

Farnum Rhonda 4

4 · Theravance Biopharma, Inc. · Filed Feb 24, 2025

Insider Transaction Report

Form 4
Period: 2025-02-10
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
Transactions
  • Award

    Ordinary Shares

    2025-02-10+5,283314,848 total
  • Tax Payment

    Ordinary Shares

    2025-02-20$9.66/sh15,810$152,725299,038 total
Footnotes (2)
  • [F1]On April 2, 2024 the reporting person was granted a performance restricted stock unit award that vests based on the achievement of certain performance conditions and continued employment. On February 10, 2025, the performance conditions were deemed achieved as to 5,283 RSUs, and such RSUs became eligible to vest based on the reporting person's continued service.
  • [F2]Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

Documents

1 file
  • 4
    form4-02252025_120248.xmlPrimary